 Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Aspirin enhances the efficacy of cisplatin in the treatment of esophageal squamous cell carcinoma

Br J Cancer: Aspirin enhances the efficacy of cisplatin in the treatment of esophageal squamous cell carcinoma

 Last Update: 2021-08-04
 Source: Internet
 Author: User

Tags

wharton's jelly stem cells

acetylsalicylic acid structure

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Esophageal cancer (EC) is the third most common cancer and the fourth leading cause of cancer death in China.
It is estimated that there are 477,900 new cases and 375,000 deaths each year
.
EC is composed of two main histopathological types: esophageal adenocarcinoma and esophageal squamous cell carcinoma (ESCC)

Esophageal cancer (EC) is the third most common cancer and the fourth leading cause of cancer death in China.

ESCC is the most important type of EC in the Chinese population, accounting for more than 90% of all cases

So far, conventional surgery, radiotherapy and chemotherapy are still the main treatment methods for ESCC, but radiotherapy and/or chemotherapy resistance and rapid tumor recurrence can lead to poor prognosis for ESCC patients
.
Previous studies have shown that cancer stem cells (CSC) are related to the prognosis, recurrence and treatment resistance of ESCC patients

Stem cell aspirin (acetylsalicylic acid, ASA) can reduce the incidence of ESCC and improve the prognosis of patients Aspirin (acetylsalicylic acid, ASA) can reduce the incidence of ESCC and improve the prognosis of patients

ASA can improve the efficacy of DDP in the treatment of esophageal squamous cell carcinoma

In this study, the researchers analyzed the role of ASA in chemotherapy/ chemoprevention in a rat ESCC carcinogenic model induced by human ESCC cell lines and NMBzA (N-nitrosomethylbenzylamine)
.
Further analyze the effect of ASA/cisplatin combination treatment on ESCC cell lines

The researchers analyzed the role of ASA in chemotherapy/ chemoprevention in a rat ESCC carcinogenic model induced by human ESCC cell lines and NMBzA (N-nitrosomethylbenzylamine)

ASA can prevent canceration of ESCC

The results show that ASA can inhibit the stem cell properties of CSC and enhance the therapeutic effect of cisplatin in human ESCC cells

All in all, the results of the study revealed that ASA may be used as a potential chemotherapy adjuvant and chemopreventive drug for ESCC treatment
.

ASA may be used as a potential chemotherapy adjuvant and chemopreventive drug for ESCC treatment
.
ASA may be used as a potential chemotherapy adjuvant and chemopreventive drug for ESCC treatment

Aspirin enhances the therapeutic efficacy of cisplatin in oesophageal squamous cell carcinoma by inhibition of putative cancer stem cells.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.